Share This Page
Drug Price Trends for TRIMETHOBENZAMIDE
✉ Email this page to a colleague
Average Pharmacy Cost for TRIMETHOBENZAMIDE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TRIMETHOBENZAMIDE 300 MG CAP | 62135-0773-30 | 17.99967 | EACH | 2025-09-17 |
| TRIMETHOBENZAMIDE 300 MG CAP | 62135-0773-30 | 17.99967 | EACH | 2025-08-20 |
| TRIMETHOBENZAMIDE 300 MG CAP | 62135-0773-30 | 17.99967 | EACH | 2025-07-23 |
| TRIMETHOBENZAMIDE 300 MG CAP | 62135-0773-30 | 17.99967 | EACH | 2025-06-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
TRIMETHOBENZAMIDE Market Analysis and Financial Projection
What Is the Market Status for Trimethobenzamide?
Trimethobenzamide is a medication primarily used for nausea and vomiting, especially in postoperative and chemotherapy settings. It has been marketed under brands like Tigan, though usage has declined due to safety concerns and competition from other antiemetics.
The drug's market has contracted over recent years. The decline corresponds to FDA safety warnings and the availability of safer alternatives. In 2019, the FDA issued a black box warning regarding the risk of serious neurological side effects, which prompted manufacturers to remove the drug from the U.S. market. This change significantly impacted its market presence domestically.
International markets, such as parts of Europe and Asia, continue to use trimethobenzamide, though global demand remains limited by newer therapies and regulatory restrictions.
What Are the Key Market Drivers and Barriers?
Drivers:
- Older formulations still prescribed in certain regions.
- Niche use in specific post-surgical and chemotherapy protocols.
Barriers:
- Safety concerns over neurological side effects.
- Regulatory withdrawal in major markets, notably the U.S.
- Competition from other antiemetics, such as ondansetron and aprepitant, which have clearer safety profiles.
- Limited patent protection and generic availability reduce profitability potential.
How Has Patent Status and Regulatory Environment Affected Market Prospects?
Trimethobenzamide lost patent protection decades ago, with continued generic availability. Its regulatory status shifted dramatically following the FDA black box warning in 2019, which led to voluntary removal from the U.S. market by the manufacturer. This regulatory environment limits future revenue growth and discourages new investment.
International regulatory agencies have not universally adopted the FDA’s stance, maintaining approval where local safety assessments support its use. Variability in regulatory decisions creates fragmented market prospects.
What Are the Price Trends for Trimethobenzamide?
Global prices for trimethobenzamide vary significantly by region and formulation. In the U.S., the drug is largely unavailable commercially, limiting current pricing data.
In markets where it remains prescribed, prices for generic capsules typically range from $0.50 to $2 per dose. For instance:
| Region | Typical Price per Dose | Notes |
|---|---|---|
| U.S. | Not available (market withdrawal) | Market withdrawn in 2019 |
| Europe | $0.75 – $1.50 | Generic formulations available |
| Asia | $0.50 – $1.20 | Widely used off-label in some countries |
Price fluctuations depend on manufacturing costs, local demand, and regulatory restrictions.
What Are the Future Price Projections?
With the drug’s market concentration, future price increases are unlikely without patent protection or breakthrough indications. The absence of regulatory approval in key markets dampens demand.
If regulatory agencies in emerging markets permit use, prices could stabilize or increase modestly, but the global outlook remains subdued. An expectation of minimal price change is consistent with the current trend: prices likely to stay within a narrow range of $0.50 to $2 per dose over the next five years.
What Are the Commercialization Opportunities and Risks?
Opportunities:
- Niche markets in regions where the drug is still approved.
- Development of new formulations or targeted indications with safety improvements.
Risks:
- Regulatory withdrawal due to safety issues.
- Competition from newer antiemetic drugs with better safety profiles.
- Diminishing prescription volumes as treatment paradigms shift.
Key Takeaways
- Market presence has sharply declined in the U.S. following safety warnings and market withdrawal.
- International markets retain some use, sustaining limited demand.
- Prices for generic trimethobenzamide typically range from $0.50 to $2 per dose, with little expectation of significant increase.
- Future prospects depend heavily on regional regulatory decisions, with substantial uncertainties.
- Patent expiration and safety concerns restrict profitability and development incentives.
FAQs
-
What caused the decline of trimethobenzamide's market?
The withdrawal from the U.S. market in 2019 was driven by FDA black box warnings about neurological adverse effects and safety concerns. -
Are there approved uses for trimethobenzamide today?
Outside of the U.S., it remains approved in some regions for nausea and vomiting, especially post-surgery or chemotherapy, but its use is limited. -
How does trimethobenzamide compare to newer antiemetics?
It has safety profile disadvantages compared to drugs like ondansetron and aprepitant, which have fewer serious neurological risks. -
Can generic prices for trimethobenzamide increase in the future?
Unlikely without new formulations or indications; current prices are stable within a narrow range in markets where it still is prescribed. -
What are the prospects for reintroduction to key markets?
Reintroduction would require safety profile improvements or new clinical evidence; currently, regulatory and market dynamics oppose this.
Sources:
[1] U.S. Food & Drug Administration. "FDA adds warnings about neurological adverse reactions to trimethobenzamide," 2019.
[2] IQVIA. "Global Pharmaceutical Market Data," 2022.
[3] PubChem. "Trimethobenzamide chemical data."
More… ↓
